A Phase I Study of ABBV-011 as a Single-Agent and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs Budigalimab (Primary) ; SC 011 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors AbbVie
- 14 Nov 2018 Planned End Date changed from 2 Sep 2022 to 26 Sep 2023.
- 14 Nov 2018 Planned primary completion date changed from 2 Sep 2022 to 26 Sep 2023.
- 14 Nov 2018 Status changed from not yet recruiting to recruiting.